Husain M, Bain SC, Jeppesen OK, Lingvay I, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab 2020 Jan 5. doi: 10.1111/dom.13955.
PMID: 31903692